Leukemia and Lymphoma

Study Finds QOL Lags in Patients With CLL, Even Before Treatment

September 12th 2020, 11:00am


Patients with chronic lymphocytic leukemia (CLL) have worse health-related quality of life scores compared to healthy controls, according to a new study out of India.

Hepatitis B More Prevalent in Patients With CLL Than Those With MM

September 10th 2020, 11:15am


New research casts doubt on the notion that hepatitis plays a role in the development of multiple myeloma (MM), finding that the virus is actually more common in chronic lymphocytic leukemia (CLL).

Identifying the Risk of Neurotoxicity After CAR T-Cell Therapy

September 4th 2020, 12:00pm


A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.

CD83 Could Be Meaningful Target Against MCL, Study Finds

September 1st 2020, 4:00am


Mantle cell lymphoma is considered incurable, but a new strategy could lead to better results in a subgroup of patients with the cancer.

Modern Therapies, Younger Age Predict Improved Outcomes in Waldenström Macroglobulinemia

August 27th 2020, 4:00am


Patients who are diagnosed with Waldenström macroglobulinemia (WM) at age 55 or younger tend to have low risk profiles and very high overall survival rates.

Levofloxacin Prophylaxis Shown to Be Cost-effective in Pediatric ALL, AML

August 25th 2020, 12:45pm


Children receiving intensive chemotherapy benefit from prophylaxis with levofloxacin to an extent that would justify the cost of the drug, a new analysis finds.

Researchers Leverage p53 Expression to Identify TP53 Missense Mutations in MCL

August 21st 2020, 4:00pm


Reporting on their findings in the British Journal of Haematology, researchers have used immunohistochemistry (IHC) to leverage p53 expression as an identifier of mantle cell lymphoma (MCL) patients carrying mutations in tumor protein p53 (TP53), an indicator of poor prognosis in the disease.

Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects

August 16th 2020, 2:00pm


Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.

TML Helps Predict Time to Treatment in CLL and Its Precursor, Study Shows

August 15th 2020, 1:00pm


Patients with chronic lymphocytic leukemia (CLL) often face months or years of uncertainty. A new study might help those patients better understand their progression timeline.

Study Explores Causes of Bleeding in Patients with CLL, MCL Taking Ibrutinib

August 14th 2020, 2:30pm


A significant proportion of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) experience bleeding when taking ibrutinib—a recent study probes why.